LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Dyslipidemia is a key target in chronic kidney disease (CKD) treatment.
• Lipid-lowering therapy aims to manage dyslipidemia in CKD patients.
• The impact of hypolipidemic drugs on low molecular weight (LMW) thiols bound to LDL in CKD requires further investigation.

Purpose of the Study:

• To evaluate the effect of different hypolipidemic drug regimens on LMW thiols and oxidative stress markers in CKD patients.
• To compare the efficacy of simvastatin monotherapy versus ezetimibe/simvastatin combination therapy.

Main Methods:

• Pilot study involving thirty CKD patients randomized into three groups.
• Treatment regimens included simvastatin alone (40 mg/day) or combined ezetimibe/simvastatin (10/20 or 10/40 mg/day).
• Evaluated LMW thiols (reduced and total forms), malondialdehyde, and allantoin/uric acid ratio.

Main Results:

• LDL thiolation decreased in all treated groups.
• Combined therapy with higher simvastatin dose (10/40 mg/day) demonstrated greater efficacy, achieving a 31% decrease in S-bound thiols after 1 year.
• This group also showed a >40% reduction in apoB-Hcy, with a concomitant decrease in oxidative stress markers.

Conclusions:

• Lipid-lowering therapy, particularly combined ezetimibe/simvastatin, effectively reduces LDL thiolation in CKD patients.
• The observed improvement in oxidative stress suggests a potential mechanism for the beneficial effects of these therapies.
• Reduced LDL-S-homocysteinylation may mitigate the antiangiogenic and proatherogenic effects on vascular endothelial cells.